Crossbow Therapeutics Inc. closed a $77 million series B round to support an ongoing phase I Crosscheck-001 trial of lead program, CBX-250, and additional T-Bolt immunotherapies targeting a broad range of cancers.
Crossbow Therapeutics Inc. has provided details on the preclinical characterization for the telomerase reverse transcriptase (TERT)-targeting T-cell engager CBX-663.
Crossbow Therapeutics Inc. has nominated its second development candidate, CBX-663, a T-cell engager for the treatment of a broad range of solid tumors and hematologic malignancies.
Cathepsin G (CTSG) is overexpressed and aberrantly localized for antigen presentation on acute myeloid leukemia blasts and stem cells compared to normal hematopoietic progenitors. Earlier this year, Crossbow Therapeutics Inc. announced the nomination of its first development candidate, CBX-250, a TCR-mimetic (TCRm) bispecific T-cell engager (TCE) antibody targeting a CTSG peptide-human leukocyte antigen (pHLA) complex and CD3.
Crossbow Therapeutics Inc. has nominated its first development candidate, CBX-250, a first-in-class, potent and specific T-cell engager (TCE) for the treatment of myeloid leukemia. CBX-250 targets a cathepsin G (CTSG) peptide-human leukocyte antigen (pHLA) complex abundantly expressed on leukemic cells, but not on normal cells.
Crossbow Therapeutics Inc. has launched with US$80 million in series A funding. The financing will allow Crossbow to advance the development of novel therapies that potently target peptide-loaded major histocompatibility complexes on cancer cells, using antibodies that mimic T-cell receptors (TCR).
Taking aim at the elusive place where stubborn cancer cells multiply, Crossbow Therapeutics Inc. has launched with $80 million in funds through a series A round. The Cambridge, Mass.-based company plans to advance its novel therapies, which mimic T-cell receptors and target peptide-loaded major histocompatibility complexes on cancer cells. If all goes well, the first product will be in the clinic in 2025.
